A novel agent for myeloma causing toxic keratopathy, belantamab mafodotin: a case report and literature review
2022

Belantamab Mafodotin and Corneal Toxicity: A Case Report

Sample size: 1 publication Evidence: low

Author Information

Author(s): Kurt Rengin Aslıhan, Gören Deniz, Karadeniz Sehnaz, Arat Mutlu, Sahin Afsun

Primary Institution: Baskent University Istanbul Hospital

Hypothesis

Can belantamab mafodotin cause corneal toxicity detectable by biomicroscopy?

Conclusion

The study highlights that belantamab mafodotin can lead to significant corneal toxicity, which may improve after discontinuation of the drug.

Supporting Evidence

  • Corneal toxicity is a common side effect of belantamab mafodotin treatment.
  • The patient experienced significant ocular symptoms after the third infusion of the drug.
  • Biomicroscopy revealed epithelial changes consistent with corneal toxicity.
  • Symptoms improved after discontinuation of the drug and treatment with eye drops.

Takeaway

A 60-year-old man had eye problems after a new cancer treatment, but his eyes got better after stopping the treatment.

Methodology

The case involved biomicroscopy and in vivo confocal microscopy to assess corneal changes.

Limitations

The study is based on a single case report, limiting generalizability.

Participant Demographics

One 60-year-old male patient with refractory relapsed multiple myeloma.

Digital Object Identifier (DOI)

10.5935/0004-2749.2021-0358

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication